



CALL FOR PAPERS

President Obama has announced the Precision Medicine Initiative, a new research effort to how we improve health and treat disease. With the increasingly available tools in genomics, this initiative will pioneer a new model of research on human diseases that promises to accelerate biomedical discoveries and translate them into new tools, knowledge, and therapies for clinicians to select which treatments will be suitable for which patients and for public health professionals to decide when and how to take preventive measures. Meanwhile, other countries have a timely active response to this initiative. It is expected that a great amount of effort will be made to biomedical research that moves towards precision medicine in next decades.

Genomics is surely a key component in the biomedical research towards the precision medicine. However, the questions about how the individual genomic variation can be used to develop new taxonomy of human diseases and how the individual environment and lifestyle are taken into account to develop treatment or intervention strategies are raised. Here we call for papers that focus on empirical analysis of genomic data with its application in precision medicine or translational research in neuropsychiatric disorders, in particular autism, attention deficit hyperactivity disorder, epilepsy, schizophrenia, bipolar, depression, and Parkinson's and Alzheimer's diseases.

Potential topics include, but are not limited to:

- ▶ Association analyses of genomic variants with human diseases or phenotypes, with an illustration of how genetic variants are used for disease classification
- ▶ Studies using the whole genome sequencing data to determine the role of common and rare variants in contributing to a disease condition
- ▶ How information on environmental exposure (both social and physical environment) and lifestyle are used to develop intervention strategies for human diseases. Studies on gene-gene and gene-environment interaction, phonemics, and molecular profiling, such as using genomics, epigenomics, proteomics, metabolomics, and lipidomics, are of interest
- ▶ Studies identifying genetic variants associated with therapeutic effects and demonstrating how genetic variants can be used for therapeutic guidance
- ▶ Commentary and review articles on risk factors associated with a specific neuropsychiatric disorder are also invited

Authors can submit their manuscripts via the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/ijg/gpmn/>.

Lead Guest Editor

Fengyu Zhang, Lieber Institute for Brain Development, Baltimore, USA
zhangf28@gmail.com

Guest Editors

Partha P. Majumder, National Institute of Biomedical Genomics, Kalyani, India
ppm1@nibmg.ac.in

Kun Xia, State Key Laboratory for Medical Genetics, Changsha, China
xiakun@sklmg.edu.cn

Xinghua Pan, Yale University, New haven, USA
xinghua.pan@yale.edu

David St. Clair, University of Aberdeen, Aberdeen, UK
d.stclair@abdn.ac.uk

Manuscript Due

Friday, 26 February 2016

First Round of Reviews

Friday, 20 May 2016

Publication Date

Friday, 15 July 2016